Poolbeg Pharma #POLB – Artificial intelligence programme yields multiple novel RSV drug targets

8 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it has made a significant breakthrough in its Artificial Intelligence (‘AI’) Programme with partner OneThree Biotech, Inc. through the discovery of novel drug targets for […]

Poolbeg Pharma #POLB – Interim results for the six months to 30 June 2022

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces its unaudited interim results for the six months to 30 June 2022. Financial & Operational Highlights • Well capitalised with a strong cash balance of £18.9m as at 30 June […]